

Allstar Health Brands Inc.

44 Greystone Crescent
Georgetown, ON Canada
L7G 1G9

Tel: (416) 918 6987
allstarglobalbrands.net
peterw@allstarhealthbrands.com

Quarterly Report

For the period ending June 30, 2026 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

350,127,579 as of June 30, 2026

321,127,580 as of December 31, 2025

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control⁵ of the company has occurred during this reporting period:

Yes: ☐ No: ☒

⁵ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Predecessor: Axxess Pharma Inc.

Axxess Pharma, Inc. was incorporated in the state of Delaware on April 7, 1997 as CGI Communications Services Inc. On July 26, 2008, the Company amended its certificate of incorporation to change its name to Axxess Pharma, Inc. On December 6, 2012 the Company reincorporated in Nevada by merging into a newly formed Nevada entity with the name Axxess Pharma, Inc. The Company now operates as a public entity Allstar Health Brands, Inc, (formerly Axxess Pharma, Inc.) with Axxess Pharma Canada, Inc. and Allstar Health Brands Inc. as its wholly owned subsidiaries.

Axxess Pharma Canada, Inc. was incorporated under the Laws of the Province of Ontario. The Company is engaged in the acquisition of Drug Identification Numbers and the eventual sale of the related products. All Star Health Brands Inc. was incorporated on October 1, 2013 under the Laws of the Province of Ontario. The Company is engaged in the acquisition of Drug Identification Numbers and the eventual sale of the related products.

The Company is currently active in its state of incorporation.

Current State and Date of Incorporation or Registration: Nevada, December 6, 2012
Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any company name change, stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

- The Company has no manufacturing or storage requirements so they do not have a plant
- All administration happens at 44 Greystone Crescent, Georgetown, ON Canada L7G1G9

Address of the issuer's principal place of business:

X Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: X Yes: ☐ If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: EQ Shareowner Services
Phone: (303) 282-4800
Email: michaelie.wingo@equiniti.com
Address: 1110 Centre Pointe Curve, Suite 101 | Mendota Heights, MN 55120

Publicly Quoted or Traded Securities:

Trading symbol:	ALST	
Exact title and class of securities outstanding:	Common	
CUSIP:	01989F109	
Par or stated value:	\$0.001	
Total shares authorized:	4,000,000,000	as of date: <u>June 30, 2026</u>
Total shares outstanding:	350,127,579	as of date: <u>June 30, 2026</u>
Number of shares in the Public Float ¹ :	316,218,323	as of date: <u>June 30, 2026</u>
Total number of shareholders of record:	624	as of date: <u>June 30, 2026</u>

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

Trading symbol:	N/A	
Exact title and class of securities outstanding:	Preferred	
CUSIP:	N/A	
Par or stated value:	\$0.001	
Total shares authorized:	<u>20,000,000</u>	as of date: <u>June 30, 2026</u>
Total shares outstanding:	<u>20,000,000</u>	as of date: <u>June 30, 2026</u>

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

The common stock has voting rights entitling the holder to one vote per share, dividends are paid at the discretion of management.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The preferred stock has voting rights but no dividend rights.

¹ "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

3. Describe any other material rights of common or preferred stockholders.

As described in 1) and 2) above

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: X (If yes, you must complete the table below)

Number of shares outstanding as of		Opening Balances	Restated Opening Balances
	Common	254,827,581	254,827,581
1-Jan-24	Preferred	20,000,000	20,000,000

Date of Transaction	Transaction Type	Number of Shares	Number of Shares restated to reflect 40,000:1 rollback Dec 23 2019	Value of shares issued \$/share	Discounted?	Issued to	Control person if issued to corporate entity	Reason for Issuance	Restricted?
June 30 2025	new issuance		40,399,999	0.001	discounted	Ramos & Ramos, 7 Roughwood Crt, North York ON	Dominic Alessandro	debt conversion	restricted
September 23 2025	new issuance		25,900,000	0.001	discounted	Ramos & Ramos, 7 Roughwood Crt, North York	Dominic Alessandro	debt conversion	restricted
March 26 2026	new issuance		28,999,999	0.001	discounted	Ramos & Ramos, 7 Roughwood Crt, North York	Dominic Alessandro	debt conversion	restricted

Net Change

95,299,998

Shares outstanding on	Closing
-----------------------	---------

June 30, 2026	Common	350,127,579
	Preferred	20,000,000

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

☐ Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (including accrued interest)	Maturity Date	Conversion Terms	Number of Shares Converted to Date	Number of Potential Shares to be Issued Upon Conversion	Name of Noteholder	Reason for Issuance
25-Feb-16	10,500	34,059	July 15, 2022	\$0.015 per share	0	2,270,599	Ramos & Ramos Investments, Dominic Alessandro	working capital
13-Nov-15	52,500	191,700	July 15, 2022	\$0.015 per share	0	12,780,026	Ramos & Ramos Investments, Dominic Alessandro	working capital
8-Oct-16	11,208	119,328	July 15, 2022	\$0.015 per share	0	7,955,182	Ramos & Ramos Investments, Dominic Alessandro	working capital
22-Apr-15	149,948	517,220	July 15, 2022	\$0.015 per share	0	34,481,341	Ramos & Ramos Investments, Dominic Alessandro	working capital
10-Dec-18	63,086	179,708	no set maturity date	none	0	179,707,925	Ramos & Ramos Investments, Dominic Alessandro	working capital
21-Jul-15	100,000	265,257	no set maturity date	50% of VMAP 20 days prior to conversion	0	265,257,331	Ramos & Ramos Investments, Dominic Alessandro	expansion, inventory and working capital
4-Jan-16	50,000	129,913	no set maturity date	50% of VMAP 20 days prior to conversion	0	129,913,491	Ramos & Ramos Investments, Dominic Alessandro	working capital
31-Dec-24	233,000	269,653	no set maturity date	\$.01 per share	0	269,652,764	Ramos & Ramos Investments, Dominic Alessandro	expansion, inventory and working capital
31-Dec-25	96,300	114,327	no set maturity date	\$.01 per share	0	114,327,360	Ramos & Ramos Investments, Dominic Alessandro	expansion, inventory and working capital
31-Dec-25	150,300	178,436	no set maturity date	\$.01 per share	0	178,436,160	Ramos & Ramos Investments, Dominic Alessandro	expansion, inventory and working capital
24-Jul-17	434,736	970,231	no set maturity date	\$.01 per share	266,815,559	970,231,013	Ramos & Ramos Investments, Dominic Alessandro	expansion, inventory and working capital
1-Jul-16	14,866	182,564	no set maturity date	60% of VMAP 20 days prior to conversion	0	182,564,380	Ramos & Ramos Investments, Dominic Alessandro	expansion, inventory and working capital
1-Oct-17	81,288	229,849	no set maturity date	50% of VMAP 20 days prior to conversion	0	229,848,538	Ramos & Ramos Investments, Dominic Alessandro	working capital
1-Apr-18	140,000	314,599	no set maturity date	50% of VMAP 20 days prior to conversion	0	314,598,502	Ramos & Ramos Investments, Dominic Alessandro	working capital

17-Oct-18	109,840	251,178	no set maturity date	50% of VMAP 20 days prior to conversion	0	251,178,172	Ramos & Ramos Investments, Dominic Alessandro	working capital
12-Oct-20	126,000	232,258	no set maturity date	50% of VMAP 20 days prior to conversion	0	232,257,693	Ramos & Ramos Investments, Dominic Alessandro	expansion, inventory and working capital
1-Oct-21	262,000	444,941	no set maturity date	50% of VMAP 20 days prior to conversion	0	444,940,678	Ramos & Ramos Investments, Dominic Alessandro	working capital
31-Dec-23	249,210	259,973	December 31, 2023	60% of VMAP 20 days prior to conversion	0	259,972,789	Ramos & Ramos Investments, Dominic Alessandro	working capital
27-May-15	25,269	88,265	no set maturity date	none	0	88,264,811	Ramos & Ramos Investments, Dominic Alessandro	debt purchased from WHC
5-Feb-15	100,000	235,984	no set maturity date	50% of VMAP 20 days prior to conversion	0	235,983,941	Ramos & Ramos Investments, Dominic Alessandro	working capital
22-Apr-15	150,000	396,161	no set maturity date	50% of VMAP 20 days prior to conversion	0	396,161,422	Ramos & Ramos Investments, Dominic Alessandro	working capital
13-Sep-15	63,000	149,685	no set maturity date	50% of VMAP 20 days prior to conversion	0	149,685,228	Ramos & Ramos Investments, Dominic Alessandro	working capital
8-Oct-15	50,000	128,846	no set maturity date	50% of VMAP 20 days prior to conversion	0	128,845,771	Ramos & Ramos Investments, Dominic Alessandro	working capital
13-Nov-15	50,000	128,075	no set maturity date	60% of VMAP 20 days prior to conversion	0	128,074,566	Ramos & Ramos Investments, Dominic Alessandro	working capital
31-Dec-25	182,000	192,920	December 31, 2026	60% of VMAP 20 days prior to conversion	0	192,920,000	Ramos & Ramos Investments, Dominic Alessandro	working capital
1-Apr-26	60,000	61,775		Par value of \$0.001	-	-	Ramos & Ramos Investments, Dominic Alessandro	Consulting services
1-Apr-26	60,000	61,775		Par value of \$0.001	-	-	Pete Wanner	Professional services
	Total outstanding balance	6,328,680		Total number of shares	266,815,559	5,400,309,684		

Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

- The Company has moved into sports and sports medicine. They have purchased a controlling interest in a lower tier women's football / soccer team. The facilities are in Italy and will compete in the next season's schedule.
- Through the Company's contacts, they have opened negotiations for training and practice facilities in both Miami and Toronto

B. List any subsidiaries, parent company, or affiliated companies.

N/A

C. Describe the issuers' principal products or services.

N/A

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company has contracted for office space in Florida. No warehouse space is currently under contract.

6) All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Peter Wanner, CGA/CPA 44 Greystone Crescent, Georgetown, ON L7G 1G9	CEO & CFO	Georgetown, ON Canada	160,000	Common	0.05%	Restricted
Blue Ivory International Holding, Ltd.	N/A	Alan Cole, Director Nassau Bahamas	20,000,000	Preferred	100%	Restricted

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name:	Anthony F. Newton, Law Office of Anthony Newton
Address 1:	16730 Creek Bend Drive
Address 2:	Sugar Land, Texas 77478
Phone:	(832) 452-0269
Email:	tony.newton@yahoo.com

Accountant or Auditor

Name:	<u>N/A</u>
Firm:	_____
Address 1:	_____
Address 2:	_____
Phone:	_____
Email:	_____

Investor Relations

Name:	<u>N/A</u>
Firm:	_____
Address 1:	_____
Address 2:	_____
Phone:	_____
Email:	_____

All other means of Investor Communication:

X (Twitter):	https://x.com/alst_allstar
Discord:	_____
LinkedIn	_____
Facebook:	_____
[Other]	_____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Peter Wanner
Firm: Peter Wanner CGA
Nature of Services: CEO and CFO
Address 1: 44 Greystone Crescent
Address 2: Georgetown, ON L7G 1G9
Phone: 416 918 6987
Email: petewanner@gmail.com

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Peter Wanner
Title: CEO and CFO
Relationship to Issuer: Contract Employee

B. The following financial statements were prepared in accordance with:

☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Peter Wanner
Title: CEO and CFO
Relationship to Issuer: Contract Employee

Describe the qualifications of the person or persons who prepared the financial statements:⁷ **CGA**

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity);
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable." Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

⁷ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

AllStar Health Brands Inc.
CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(Amounts expressed in US Dollars)
June 30, 2026
Table of Contents

	Page
Consolidated Balance Sheets	2
Consolidated Statements of Operations and Comprehensive Loss	3
Consolidated Statements of Stockholders' Deficit	4
Consolidated Statements of Cash Flows	5
Notes to Financial Statements	6

TO THE STOCKHOLDERS OF ALLSTAR HEALTH BRANDS INC.

The consolidated balance sheets of AllStar Health Brands Inc. at June 30, 2026 and December 31 2025 and the consolidated Statements of Operations and Comprehensive Loss, Changes in Stockholders' Deficit and Cash Flows for the periods then ended have not been audited by the Company's auditors. These financial statements are the responsibility of management and have been reviewed and approved by the Company's audit committee and Board of Directors

AllStar Health Brands INC
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Amounts expressed in US Dollars)

	<u>June 30 2026</u>	<u>December 31 2025</u>
ASSETS		
Current Assets		
Cash	\$ 165	\$ 1,483
Prepaid expenses	90,000	-
TOTAL CURRENT ASSETS		
INTANGIBLE ASSETS		
TOTAL ASSETS	<u>\$ 90,165</u>	<u>\$ 1,483</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable and accrued liabilities	3,818,053	3,522,463
License fee payable	5,000,000	5,000,000
Convertible notes payable	875,512	875,512
Convertible notes payable - related party	2,079,540	2,082,440
Due to stockholders	319,971	-
TOTAL CURRENT LIABILITIES	<u>12,093,076</u>	<u>11,480,415</u>
TOTAL LIABILITIES	<u>12,093,076</u>	<u>11,480,415</u>
Going concern (note 3)		
Related party transactions (note 4)		
Commitments and contingencies (note 9)		
Subsequent event (note 10)		
STOCKHOLDERS' EQUITY		
Preferred stock \$0.001 par value; 20,000,000 authorized shares; 20,000,000 shares issued and outstanding (note 5)	2,000	2,000
Common Stock, \$0.001 par value; 4,000,000,000 authorized shares; 350,127,579 issued and outstanding shares as of June 30, 2026 and 321,127,580 issued and outstanding shares as of December 31, 2025 (note 5)	35,013	32,113
Additional paid-in capital	46,444,628	46,433,028
Common stock payable	6,000	6,000
Other comprehensive loss	(45,409)	(45,409)
Retained earnings	(58,445,142)	(57,906,663))
TOTAL STOCKHOLDERS' EQUITY	<u>(12,002,911)</u>	<u>(11,478,932))</u>
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	<u>\$ 90,165</u>	<u>\$ 1,483</u>

The accompanying notes are an integral part of these interim consolidated financial statements.

Signed "Peter Wanner"

CEO and CFO

AllStar Health Brands INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(Amounts expressed in US Dollars)

	6 Months Ended Jun 30		3 Months Ended Jun 30	
	2026	2025	2026	2025
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	\$	\$	\$	\$
REVENUE	-	-	-	-
COST OF GOODS SOLD	-	-	-	-
GROSS PROFIT	-	-	-	-
EXPENSES				
Professional fees	179,575	71,650	80,113	51,650
Office	19,440	14,845	11,285	12,596
Advertising	-	3,370	-	3,370
Travel and related	11,661	14,419	3,177	6,310
Bank charges	1,203	1,048	604	535
TOTAL OPERATING EXPENSES	211,879	105,332	95,177	74,461
NET LOSS FROM OPERATIONS	211,879	105,332	95,177	74,461
OTHER INCOME/EXPENSE				
Interest expense	315,000	274,000	157,500	137,000
Loss on debt conversion	11,600	-	-	-
TOTAL OTHER INCOME /EXPENSE	326,600	274,000	157,500	137,000
NET LOSS BEFORE INCOME TAXES	538,479	379,332	252,677	211,461
INCOME TAX EXPENSE	-	-	-	-
NET LOSS	538,479	379,332	252,677	211,461
OTHER COMPREHENSIVE LOSS	-	-	-	-
NET LOSS & COMPREHENSIVE LOSS	538,479	379,332	252,677	211,461
Basic & Diluted loss per share (Note 7)	0.00	0.00	0.00	0.00
Weighted average basic & diluted shares outstanding	350,127,579	295,227,580	350,127,579	254,827,581

The accompanying notes are an integral part of these interim consolidated financial statements.

AllStar Health Brands INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
(Unaudited)
(Amounts expressed in US Dollars)

	Preferred stock		Common stock		Common Stock	Other	Additional	Deficit	Total
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Payable</u>	<u>Comprehensive</u>	<u>Paid in Capital</u>	<u>Accumulated</u>	
Balance, December 31, 2017	20,000,000	\$ 2,000	63,766	\$ 6	\$ 6,000	\$ (45,409)	\$ 36,125,535	\$ (47,893,705)	\$ (11,805,572)
Debt Converted to Equity	-	-	35,311	3	-	-	820,605	-	820,608
Net loss	-	-	-	-	-	-	-	(542,577)	(542,577)
Balance, December 31, 2018	20,000,000	\$ 2,000	99,077	\$ 9	\$ 6,000	\$ (45,409)	\$ 36,946,140	\$ (48,436,282)	\$ (11,527,541)
Debt Converted to Equity	-	-	-	-	-	-	2,246,458	-	2,246,458
Common stock issued	-	-	1,215,313	122	-	-	626,820	-	626,942
Net loss	-	-	-	-	-	-	-	(872,983)	(872,983)
Balance, December 31, 2019	20,000,000	2,000	1,314,390	131	6,000	(45,409)	39,819,418	(49,309,265)	(9,527,125)
Debt Converted to Equity	-	-	9,515,572	952	-	-	4,890,787	-	4,891,739
Common stock issued	-	-	140,000	14	-	-	-	-	14
Stock compensation	-	-	270,000	27	-	-	13,973	-	14,000
Net loss	-	-	-	-	-	-	-	(3,866,427)	(3,866,427)
Balance, December 31, 2020	20,000,000	2,000	11,239,962	1,124	6,000	(45,409)	44,724,178	(53,175,692)	(8,487,799)
Debt Converted to Equity	-	-	-	-	-	-	-	-	-
Common stock issued	-	-	40,442,102	4,044	-	-	1,154,491	-	1,158,535
Stock compensation	-	-	-	-	-	-	-	-	-
Net loss	-	-	-	-	-	-	-	(1,450,545)	(1,450,545)
Balance, December 31, 2021	20,000,000	2,000	51,682,064	5,168	6,000	(45,409)	45,878,669	(54,626,237)	(8,779,809)
Debt Converted to Equity	-	-	168,942,161	16,894	-	-	534,951	-	551,845
Common stock issued	-	-	-	-	-	-	-	-	-
Stock compensation	-	-	30,000	3	-	-	-	-	3
Net loss	-	-	-	-	-	-	-	(605,590)	(605,590)
Balance, December 31, 2022	20,000,000	2,000	220,654,225	22,066	6,000	(45,409)	46,413,619	(55,231,827)	(8,833,551)
Debt Converted to Equity	-	-	-	-	-	-	-	-	-
Common stock issued	-	-	34,173,356	3,417	-	-	26,039	-	29,456
Stock compensation	-	-	-	-	-	-	-	-	-
Net loss	-	-	-	-	-	-	-	(499,343)	(499,343)
Balance, December 31, 2023	20,000,000	2,000	254,827,581	25,483	6,000	(45,409)	46,439,658	(55,731,169)	(9,303,435)
Common stock issued	-	-	-	-	-	-	-	-	-
Stock compensation	-	-	-	-	-	-	-	-	-
Net loss	-	-	-	-	-	-	-	(1,426,701)	(1,426,701)
Balance, December 31, 2024	20,000,000	2,000	254,827,581	25,483	6,000	(45,409)	46,439,658	(57,157,870)	(10,730,138)
Common stock issued	-	-	66,299,999	6,630	-	-	(6,630)	-	-
Stock compensation	-	-	-	-	-	-	-	-	-
Net loss	-	-	-	-	-	-	-	(748,793)	(748,793)
Balance, December 31, 2025	20,000,000	2,000	321,127,580	32,113	6,000	(45,409)	46,433,028	(57,906,663)	(11,478,932)
Debt converted to equity	-	-	28,999,999	2,900	-	-	11,600	-	14,500
Net loss	-	-	-	-	-	-	-	(538,479)	(538,479)
Balance, June 30, 2026	20,000,000	2,000	350,127,579	35,013	6,000	(45,409)	46,444,628	(58,445,142)	(12,002,911)

AllStar Health Brands INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Amounts expressed in US Dollars)

	June 30	
	2026	2025
OPERATING ACTIVITIES		
Net loss	\$ 538,479	\$ 379,322
Adjustments to reconcile net income to net cash provided by operating activities:		
Increase in Accounts payable & accrued liabilities	295,590	379,203
Increase in Prepaid expenses	(90,000)	-
Net cash (used) / provided by operating activities	(332,889)	(119)
FINANCING ACTIVITIES		
Advances from stockholders	319,971	-
Proceeds from notes payable	-	-
Proceeds from note payable, related party	11,600	-
Net cash provided by financing activities	331,571	-
Effect of foreign currency translation		
NET INCREASE (DECREASE) IN CASH	(1,318)	(119)
Beginning of period	1,483	189
End of Period	\$ 165	\$ 70
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION		
Income taxes paid	\$ -	\$ -
Interest paid	\$ -	\$ -
NON-CASH ACTIVITY		
Loss on debt conversion	\$ -	\$ -
Conversion of debt to equity	\$ -	\$ -

The accompanying notes are an integral part of these interim consolidated financial statements.

AllStar Health Brands INC.
Notes to Consolidated Financial Statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 1—THE COMPANY AND BASIS OF PRESENTATION

Nature of operations

Axxess Pharma, Inc. was incorporated in the state of Delaware on April 7, 1997 as CGI Communications Services Inc. On July 26, 2008, the Company amended its certificate of incorporation to change its name to Axxess Pharma, Inc. On December 6, 2012 the Company reincorporated in Nevada by merging into a newly formed Nevada entity with the name Axxess Pharma, Inc. The Company now operates as Axxess Pharma, Inc. with Axxess Pharma Canada, Inc. and Allstar Health Brands Inc. as its wholly owned subsidiaries.

Axxess Pharma Canada, Inc. was incorporated under the Laws of the Province of Ontario. The Company is engaged in the acquisition of Drug Identification Numbers and the eventual sale of the related products. All Star Health Brands Inc. was incorporated on October 1, 2013 under the Laws of the Province of Ontario.

The consolidated financial statements included the results of Axxess Pharma Inc. Axxess Pharma Canada and its wholly owned subsidiary Allstar Health Brands Inc. All intercompany accounts have been eliminated on consolidation.

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

The Company's most significant areas of estimation and assumption are:

- determination of the appropriate amount and timing of markdowns to clear unproductive or slow-moving retail inventory and overall inventory obsolescence
- estimation of future cash flows used to assess the recoverability of long-lived assets
- estimation of fair value of the equity instruments

Cash and Cash Equivalents

All short-term investments with original maturities of three months or less at date of purchase are considered cash equivalents.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and accounts receivable. The Company maintains their cash in bank deposit accounts at high credit quality financial institutions. The balances, at times, may exceed federally insured limits. The Company also maintains a certain amount of cash on hand at the retail store locations. The Company has not experienced any significant losses with respect to its cash. At both June 30, 2026 and December 31, 2025, the Company did not exceed the insured limit of a depository institution.

AllStar Health Brands INC.
Notes to Consolidated Financial Statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont'd)

Fair value of financial instruments

The carrying amounts reported in the balance sheets for cash, accounts payable and accrued expenses approximate their fair values based on the short-term maturity of these instruments. The carrying amounts of the Company's promissory note obligations approximate their fair value, as the terms of these notes are consistent with terms available in the market for instruments with similar risk.

We account for our derivative financial instruments, consisting solely of certain stock purchase warrants that contain non-standard anti-dilutions provisions and/or cash settlement features, and certain conversion options embedded in our convertible instruments, at fair value using level 1 inputs. We determine the fair value of these derivative liabilities using the Black-Scholes option pricing model when appropriate, and in certain circumstances using binomial lattice models or other accepted valuation practices.

When determining the fair value of our financial assets and liabilities using the Black-Scholes option pricing model, we are required to use various estimates and unobservable inputs, including, among other things, contractual terms of the instruments, expected volatility of our stock price, expected dividends, and the risk-free interest rate. Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the instrument. Increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value.

Foreign Currency Transactions

The Company's functional currency is the Canadian dollar and the reporting currency is the U.S. dollar. Assets and liabilities are translated from the functional to the reporting currency at the exchange rate in effect at the balance sheet date, and equity at the historical exchange rates. Revenue and expenses are translated at rates in effect at the time of the transactions. Resulting translation gains and losses are accumulated in a separate component of stockholders' equity - other comprehensive income (loss). Realized foreign currency transaction gains and losses are credited or charged directly to operations.

Revenue recognition

The Company derives revenues from sale of merchandise and upon the following: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered, (3) the seller's price to the buyer is fixed or determinable, and (4) collectability is reasonably assured.

Advertising / Marketing

Advertising costs are charged to expense when incurred. The Company's advertising method is primarily print, web-based social media and industry contacts. Advertising / marketing costs were \$nil and \$nil for the periods ended June 30, 2026 and June 30, 2025, respectively.

AllStar Health Brands INC.
Notes to Consolidated Financial Statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Stock-based compensation

The Company records stock-based compensation in accordance with the guidance in ASC Topic 505 and 718 which requires the Company to recognize expenses related to the fair value of its employee stock option awards. This eliminates accounting for share-based compensation transactions using the intrinsic value and requires instead that such transactions be accounted for using a fair-value-based method. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award.

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 718-10 and the conclusions reached by the FASB ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration, other than employee services, is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.

Comprehensive Income

ASC Topic 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income and its components in a full set of general-purpose financial statements. Comprehensive Income consists of foreign currency translation.

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not expect the future adoption of any such pronouncements to have a significant impact on its results of operations, financial condition or cash flow.

NOTE 3 – GOING CONCERN

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of \$58,445,142 as of June 30 2026, and further losses are anticipated in the development of its business raising substantial doubt about the Company's ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities, which have arisen from normal business operations as they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand, loans from our director and/or private placements of common stock.

AllStar Health Brands INC.
Notes to Consolidated Financial Statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 4 – CONVERTIBLE PROMISSORY NOTES PAYABLE

Convertible promissory notes, including accrued interest, at June 30, 2026 and December 31, 2025 are as follows:

	2026	2025
RBB Capital, WHC assignment May 27, 2015, including accrued interest of \$62,996 and \$58,793, respectively	\$ 88,265	\$ 84,062
Carrollton Partners, December 10, 2018, including accrued interest of \$116,622 and \$101,784, respectively	179,708	164,870
Ramos and Ramos, October 12, 2020, including accrued interest of \$106,258 and \$93,111, respectively	232,258	219,111
Redwood Capital, February 5, 2015, including accrued interest of \$135,984 and \$124,747, respectively	235,984	224,747
Redwood Capital, April 22, 2015, including accrued interest of \$246,161 and \$223,737, respectively	396,161	373,737
Redwood Capital, October 8, 2016, including accrued interest of \$75,199 and \$71,553, respectively	128,846	121,553
Redwood Capital, November 13, 2015, including accrued interest of \$78,846 and \$70,825, respectively	128,075	120,825
Redwood Global Fund III, August 14, 2015, including accrued interest of \$86,685 and \$79,557, respectively	149,685	142,557
Ramos and Ramos, July 24, 2017, including accrued interest of \$535,495 and \$489,294, respectively	970,231	924,030
Ramos and Ramos, LLC, July 1, 2016, including accrued interest of \$167,698 and \$157,365, respectively	182,564	175,131
Ramos and Ramos, LLC, October 1, 2017, including accrued interest of \$148,561 and \$135,550, respectively	229,849	216,838
GHS Investments, July 21, 2015, including accrued interest of \$165,257 and \$150,243, respectively	265,257	250,243
GHS Investments, January 4, 2016, including accrued interest of \$79,913 and \$72,560, respectively	129,913	122,560
Ramos and Ramos, October 17, 2018, including accrued interest of \$148,561 and \$127,121, respectively	251,179	236,961
Ramos and Ramos, April 1, 2018, including accrued interest of \$174,599 and \$156,791, respectively	314,599	296,791
BOU Trust, February 25, 2016, including accrued interest of \$23,559 and \$21,937, respectively	34,059	32,437
BOU Trust, November 13, 2016, including accrued interest of \$139,200 and \$130,072, respectively	191,700	182,572
BOU Trust, October 8, 2016, including accrued interest of \$108,120 and \$102,437, respectively	119,328	113,645
BOU Trust, April 22, 2016, including accrued interest of \$367,272 and \$342,643, respectively	517,220	492,591
Ramos and Ramos, October 1, 2021, including accrued interest of \$182,941 and \$157,755, respectively	444,941	419,755
Ramos and Ramos, December 31, 2023, including accrued interest of \$10,763 and \$9,212, respectively	259,973	258,422
Ramos and Ramos, December 31, 2024, including accrued interest of \$36,653 and \$28,799, respectively	269,653	261,799
Ramos and Ramos, December 31, 2025, including accrued interest of \$18,027 and \$11,556, respectively	114,327	107,856
Ramos and Ramos, December 31, 2025, including accrued interest of \$28,136 and \$18,036, respectively	178,436	168,336
Ramos and Ramos, December 31, 2026, including accrued interest of \$10,920 and \$nil, respectively	192,920	182,000

AllStar Health Brands INC.
Notes to Consolidated financial statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 4 – CONVERTIBLE PROMISSORY NOTES PAYABLE (cont'd)

Ramos and Ramos, April 1, 2026, including accrued interest of \$1,775 and \$nil respectively	61,775	-
Pete Wanner, April 1, 2026, including accrued interest of \$1,775 and \$nil respectively	61,775	-
Convertible promissory notes payable, net	\$ 6,328,680	\$ 5,893,428

We evaluated the convertible promissory notes transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion features of the convertible promissory notes were not afforded the exemption for conventional convertible instruments due to their respective variable conversion rate. The notes have no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically according to the stock price fluctuations.

WHC Assignment/RBB Capital

On May 27, 2015, WHC Investments, Inc. assigned \$175,000 to RBB Capital pursuant to the terms of the \$312,500 WHC Convertible Promissory note, dated November 4, 2014. The note may be converted in the event that (a) the note is in default or (b) the net proceeds from the sale of collateral shares do not provide adequate coverage of all amounts due. The note is convertible into the Company's common stock at an initial conversion price at 70% of the average three daily volume weighted averages during the 20 days before the issue date. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of six (6) months. The original balance of the loan has been reduced through a series of conversions to common shares. The current principal balance amounted to \$25,269 and accrued interest of \$62,996 and \$58,793, as of June 30, 2026 and December 31, 2025, respectively.

Redwood Global Fund III

On August 14, 2015, the Company entered into a note payable with Redwood Global Fund III. The agreement exchanged notes of \$63,000, includes \$3,000 of original issuance discount and bears interest at a 10% per annum interest rate. The note matured on August 14, 2016 and is secured by the share reservation of 100% of the number of share of common stock issuable upon a conversion. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) of the volume-weighted averages the twenty (20) days preceding the date of conversion. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of twelve (12) months. The Company recorded amortization of debt discount and original issuance discount, which was recognized as interest expense, in the amount of \$29,227 and \$1,861 during the period ending December 31, 2016, respectively. The balance as of June 30, 2026 and December 31, 2025, amounted to \$149,685 and \$129,598, comprised of a principal balance of \$63,000 and accrued interest of \$86,685 and \$79,557, respectively.

Ramos and Ramos Investments, Inc

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$300,000 with Ramos and Ramos Investments, Inc dated October 20, 2015. The note payable bears interest at a 10% per annum. The note matured on October 20, 2016 and is secured by the share reservation of 100% of the number of share of common stock issuable upon a conversion. The note is convertible into shares of common stock at a price equal to a variable conversion price of seventy five percent (75%) of the lowest bid price in the thirty (30) days preceding the date of conversion. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of one year. On July 24, 2017, Ramos and Ramos Investments put forth a default notice for non-payment of the convertible promissory note payable and related accrued interest. Ramos and Ramos Investments demanded the note payable, accrued interest and liquidated damages of \$224,500 amounting to an aggregate \$600,000 convertible note balance and a reserve of one and one-half (1.5) billion shares of the Company's common stock. In addition to the liquidated damages, on August 1, 2017, the Company satisfied the default notice with the reservation of one (1) billion shares the Company's common stock. The balance as of June 30, 2026 and December 31, 2025 has been reduced through a series of debt conversions to common shares and amounted to \$970,231 and \$840,027, comprised of the current principal balance of \$489,294 and accrued interest of \$535,495 and \$405,291, respectively.

AllStar Health Brands INC.
Notes to Consolidated Financial Statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 4 – CONVERTIBLE PROMISSORY NOTES PAYABLE (cont'd)

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$100,000 with Ramos and Ramos Investments, Inc., dated July 1, 2016. The note payable bears interest at 12% per annum. The note matured on January 1, 2016. The note is convertible into shares of common stock at a price equal to a variable conversion price of seventy five percent (75%) of the lowest bid price in the five (5) days preceding the date of conversion. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of six (6) months. The principal balance and accrued interest have been reduced through a series of debt conversions to common shares. The balance as of June 30, 2026 and December 31, 2025, amounted to \$182,564 and \$156,367, comprised of the principal balance of \$17,766, reduced through a series of conversions, and accrued interest of \$167,698 and \$157,365, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$140,000 with Ramos and Ramos Investments, Inc. exchanging certain accounts payable and prior advances, dated October 1, 2017. The note payable bears interest at 12% per annum. The note, which matured on March 30, 2018, is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) of the lowest bid price in the five (5) days preceding the date of conversion. The fair value of the note has been determined using the Black-Scholes pricing model with an expected life of six (6) months. The balance as of June 30, 2026 and December 31, 2025 has been reduced through a series of debt conversions to common shares and amounted to \$229,849 and \$193,606, respectively, comprising of a principal balance of \$81,288 and accrued interest of \$148,561 and \$135,550, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$140,000 with Ramos and Ramos Investments, Inc. exchanging certain accounts payable and prior advances, dated April 1, 2018. The note payable bears interest at 12% per annum. The note matured on September 30, 2019. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) of the lowest bid price in the twenty (20) days preceding the date of conversion. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of six (6) months. The balance as of June 30, 2026 and December 31, 2025 amounted to \$314,599 and \$264,992, respectively, comprised of a principal balance of \$140,000 and accrued interest of \$174,599 and \$156,791, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$139,125 with Ramos and Ramos Investments, Inc. exchanging certain accounts payable and prior advances, dated October 17, 2018. The note payable bears interest at 12% per annum. The note matured on April 17, 2019. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) of the lowest bid price in the twenty (20) days preceding the date of conversion. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of six (6) months. The balance as of June 30, 2026 and December 31, 2025 amounted to \$251,179 and \$211,572, respectively, comprised of principal balance of \$109,840, reduced by a series of debt conversions, and accrued interest of \$141,338 and \$127,121, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$126,000 with Ramos and Ramos Investments, Inc., dated October 12, 2020. The note payable bears interest at 12% per annum and matured on April 12, 2021. The note is convertible into shares of common stock at a price equal to a variable conversion price of thirty five percent (35%) of the lowest bid price in the twenty (20) days preceding the date of conversion. The balance as of June 30, 2026 and December 31 2025 amounted to \$232,258 and \$195,635, respectively, comprised of principal balance of \$126,000 and accrued interest of \$106,258 and \$93,111, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$262,000 with Ramos and Ramos Investments, Inc., dated October 1, 2021. The note payable bears interest at 12% per annum and matured on April 1, 2022. The note is convertible into shares of common stock at a price equal to a variable conversion price of thirty five percent (35%) of the lowest bid price in the twenty (20) days preceding the date of conversion. The balance as of June 30, 2026 and December 31, 2025 amounted to \$444,941 and \$374,782, respectively, comprised of a principal balance of \$262,000 and accrued interest of \$182,941 and \$157,755, respectively.

AllStar Health Brands INC.
Notes to Consolidated Financial Statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 4 – CONVERTIBLE PROMISSORY NOTES PAYABLE (cont'd)

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$260,000 with Ramos and Ramos Investments, Inc., dated December 31, 2022. The note payable bears interest at 1.2% per annum and matured on December 31, 2023. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) of the lowest volume weighted average price in the twenty (20) trading days preceding the date of conversion. The balance as of June 30, 2026 and December 31, 2025 amounted to \$259,973 and \$255,358, respectively, comprised of principal balance of \$260,000 and accrued interest of \$10,763 and \$9,212, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$233,000 with Ramos and Ramos Investments, Inc., dated January 1, 2024. The note payable bears interest at 6% per annum and matured on December 31, 2024. Any amount of principal or interest which is not paid when due shall bear interest at the rate of 12% per annum. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) discount off of lowest volume weighted average price in the twenty (20) trading days immediately preceding the date of conversion.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$269,653 and \$246,980, respectively, comprised of principal balance of \$233,000 and accrued interest of \$36,653 and \$28,799, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$96,300 with Ramos and Ramos Investments, Inc., dated December 31, 2024. The note payable bears interest at 12% per annum and matured on December 31, 2025. Any amount of principal or interest which is not paid when due shall bear interest at the rate of 16% per annum. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) discount off of lowest volume weighted average price in the twenty (20) trading days immediately preceding the date of conversion.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$114,327 and \$96,300, respectively, comprised of principal balance of \$96,300 and accrued interest of \$18,027 and \$11,556, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$150,300 with Ramos and Ramos Investments, Inc., dated December 31, 2024. The note payable bears interest at 12% per annum and matured on December 31, 2025. Any amount of principal or interest which is not paid when due shall bear interest at the rate of 16% per annum. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) discount off of lowest volume weighted average price in the twenty (20) trading days immediately preceding the date of conversion.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$178,436 and \$150,300, respectively, comprised of principal balance of \$150,300 and accrued interest of \$28,136 and \$18,036, respectively.

The Company entered into a convertible promissory note payable in an aggregate principal amount of \$182,000 with Ramos and Ramos Investments, Inc., dated December 31, 2025. The note payable bears interest at 12% per annum and matures on December 31, 2026. Any amount of principal or interest which is not paid when due shall bear interest at the rate of 18% per annum. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (60%) discount off of lowest volume weighted average price in the twenty (20) trading days immediately preceding the date of conversion.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$192,920 and \$182,000, respectively, comprised of a principal balance of \$182,000 and accrued interest of \$10,920 and \$nil, respectively.

AllStar Health Brands INC.
Notes to Consolidated financial statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 4 – CONVERTIBLE PROMISSORY NOTES PAYABLE (cont'd)

Carrollton Partners, LLC

The Company entered into a convertible promissory note payable in the amount of \$63,086 with Carrollton Partners, LLC., dated December 10, 2018. The note payable bears interest at 12% per annum. The note matured on June 30, 2019. The note bears interest at 6% in the event of a default, which includes non-payment of the note amount, plus all accrued interest, on maturity date.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$179,708 and \$139,720, respectively, comprised of principal balance of \$63,086 and accrued interest of \$116,622 and \$101,784, respectively.

GHS Investments, Inc.

On July 21, 2015 the Company entered into a convertible promissory note payable in an aggregate principal amount of \$100,000 with GHS Investments, Inc. The note bears interest at 12% per annum and any amount of the principal or interest not paid when due shall bear interest at the rate of 22% per annum from the due date thereof until paid. The note matured nine months upon receipt by the Company. The note is convertible into shares of common stock at a price equal to a variable conversion price of sixty percent (65%) of the lowest volume-weighted average in the twenty (20) days preceding the date of conversion.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$265,257 and \$223,431, comprised of a principal balance of \$100,000 and accrued interest of \$165,257 and \$150,243, respectively.

On January 4, 2016, the Company entered into a convertible promissory note payable in an aggregate principal amount of \$50,000 with GHS Investments, Inc. The note bears interest at 12% per annum and any amount of the principal or interest not paid when due shall bear interest at the rate of 22% per annum from the due date thereof until paid. The note matured nine months upon receipt by the Company. The note is convertible into shares of common stock at a price equal to a variable conversion price of fifty percent (50%) of the lowest volume-weighted average in the twenty (20) days preceding the date of conversion. The fair value of the note has been determined by using the Black-Scholes pricing model with an expected life of six (6) months.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$129,913 and \$109,428, comprised of principal balance of \$50,000 and accrued interest of \$79,913 and \$72,560, respectively.

BOU Trust

On October 8, 2016, the Company entered into a convertible note payable with BOU Trust. The \$52,500 note bears interest at 10% per annum. The note had an initial maturity date of August 25, 2016; pursuant to a Trust Debenture Modification Agreement, its maturity was extended to July 15, 2022. The note is secured by the share reservation of 300% of the number of shares of common stock issuable upon a conversion. The note is convertible into shares of common stock at a fixed price of \$0.015 per share. The fair value of the note has been determined using the Black-Scholes pricing model with an expected life of six (6) months.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$119,328 and \$103,314, comprised of principal balance of \$11,208, reduced by a series of debt conversions, and accrued interest of \$108,120 and \$102,437, respectively.

On February 25, 2016, the Company entered into a convertible note payable with BOU Trust. The \$10,500 note bears interest at 10% per annum. The note had an initial maturity date of August 25, 2016; pursuant to a Trust Debenture Modification Agreement, its maturity was extended to July 15, 2022. The note is secured by the share reservation of 300% of the number of shares of common stock issuable upon a

AllStar Health Brands INC.
Notes to Consolidated financial statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 4 – CONVERTIBLE PROMISSORY NOTES PAYABLE (cont'd)

conversion. The note is convertible into shares of common stock at a fixed price of \$0.015 per share. The fair value of the note has been determined using the Black-Scholes pricing model with an expected life of six (6) months.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$34,059 and \$29,488, comprised of principal balance of \$10,500, reduced by a series of debt conversions, and accrued interest of \$23,559 and \$21,937, respectively.

On November 13, 2015, the Company entered into a convertible note payable with BOU Trust. The \$52,500 note bears interest at 10% per annum. The note had an initial maturity date of August 25, 2016; pursuant to a Trust Debenture Modification Agreement, its maturity was extended to July 15, 2022. The note is secured by the share reservation of 300% of the number of shares of common stock issuable upon a conversion. The note is convertible into shares of common stock at a fixed price of \$0.015 per share. The fair value of the note has been determined using the Black-Scholes pricing model with an expected life of six (6) months.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$191,700 and \$165,974, comprised of a principal balance of \$52,500, reduced by a series of debt conversions, and accrued interest of \$139,200 and \$130,072, respectively.

On April 22, 2015, the Company entered into a convertible note payable with BOU Trust. The \$175,000 note bears interest at 10% per annum. The note had an initial maturity date of August 25, 2016; pursuant to a Trust Debenture Modification Agreement, its maturity was extended to July 15, 2022. Through a series of debt conversions, the principal balance of the note has been reduced to \$149,948. The note is secured by the share reservation of 300% of the number of shares of common stock issuable upon a conversion. The note is convertible into shares of common stock at a fixed price of \$0.015 per share. The fair value of the note has been determined using the Black-Scholes pricing model with an expected life of six (6) months.

The balance as of June 30, 2026 and December 31, 2025 amounted to \$517,220 and \$447,810, comprised of a principal balance of \$149,948, reduced by a series of debt conversions, and accrued interest of \$367,272 and \$342,643, respectively.

AllStar Health Brands INC.
Notes to Consolidated Financial Statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 5 – EQUITY

Preferred stock

At June 30 2026, the Company has 20,000,000 of Series A preferred stock with a par value of \$0.0001 per share.

Of the 20,000,000 shares of authorized preferred stock, 20,000,000 shares are issued and outstanding as of June 30, 2026 and December 31, 2025.

On April 15, 2015, the Company entered into a certificate of designation with the State of Nevada designating the preferred shares as Series A Preferred with a \$1.00 liquidation preference and no dividend rights. The preferred stock has voting rights, regardless of the number of shares outstanding, representing 80% of all votes entitled to be voted.

Common stock

On December 14, 2020, the Company increased its authorized common stock from 1,000,000,000 to 4,000,000,000, all with a par value of \$0.001 per share. The common stock has voting rights and entitles to one vote per share. Of the 4,000,000,000 shares of authorized common stock, 350,127,579 were issued and outstanding as of June 30, 2026 and December 31, 2025.

The following common stock transactions occurred during the six months ended June 30, 2026:

During the period, 28,999,999 shares were issued to an existing shareholder at par value.

The following common stock transactions occurred during the six months ended June 30 2025:

During the period, 40,399,999 shares were issued to an existing shareholder at par value.

NOTE 6 – FAIR VALUE OF FINANCIAL INSTRUMENTS

Disclosures about fair value of financial instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2026 the amounts reported for cash, accrued interest and other expenses, notes payables, and derivative liability approximate their fair value because of their short maturities.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

- Level 1, defined as observable inputs, such as quoted prices, for identical instruments in active markets;
- Level 2, defined as inputs other than quoted prices in active markets, that are either directly or indirectly observable, such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
- Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

AllStar Health Brands INC.
Notes to Consolidated financial statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 7 – LOSS PER SHARE

The following table presents the computations of basic and dilutive loss per share:

	June 30, 2026	June 30, 2025
Net loss	\$ 538,479	\$ 379,322
Net loss per share:		
Net loss per share – basic and diluted	\$ 0.00	\$ 0.00
Weighted average common shares outstanding – basic and diluted	350,127,579	295,227,580

NOTE 8 — INCOME TAXES

On December 22, 2017 the Tax Cuts and Jobs Act (“TCJA”) was signed into law. Pursuant to Staff Accounting Bulletin No 118, a reasonable estimate of the specific income tax effects for the TCJA can be determined and the Company is reporting these provisional amounts. Accordingly, the Company may revise these estimates in the upcoming years.

The TCJA reduces the corporate income tax rate from 34% to 21% effective January 1, 2018. All deferred income tax assets and liabilities, have been re-measured using the new rate under the TCJA and are reflected in the valuation of these assets as of December 31, 2017. As a result of the re-measurement, the value of our net deferred tax asset has decreased by approximately \$5,900,000.

Net operating losses arising after January 1, 2018, can be carried forward indefinitely but they can only offset 80% of the net income in any one of the subsequent years. The net operating losses cannot be carried back.

The provision for federal income tax consists of the following:

	June 30, 2026	June 30, 2025
Federal income tax benefit attributable to:		
Current operations	\$ 113,081	79,660
Non-deductible expenses	(113,081)	(79,660)
Less: valuation allowance	-	-
Net provision for Federal income taxes	\$ -	-

AllStar Health Brands INC.
Notes to Consolidated financial statements
June 30, 2026
(Unaudited)
(Amounts expressed in US Dollars)

NOTE 9 — COMMITMENTS AND CONTINGENCIES

Joint venture agreement

In August 2019, the Company signed a memorandum of understanding with an unrelated party to establish a joint venture with an equal sharing of profits from the sales of pharmaceuticals of both parties to the agreement.

Consulting Agreements

The Company entered into a consulting agreement, dated April 1, 2017, with Ramos & Ramos Investments, Inc ('the Consultant'). The Consultant will be compensated \$5,000 per month upon the attainment of capital investment by the Company. Furthermore, the Company will issue common stock to the Consultant to the extent payments are outstanding.

On April 1, 2019, the Company entered into a consulting agreement with a third party. As compensation for consulting services, the Company will be paid a quarterly fee of \$20,000, a fee of 5% of the amount of capital acquired on behalf of the third party, and an additional fee of 5% of the amount of common shares.

On February 1, 2020, the Company entered into a consulting agreement with Peter Wanner, to provide CFO duties. The Company will pay an hourly rate for the hours expended, and settled past compensation with the immediate issuance of 50,000 restricted shares. The agreement allows for the additional earning of 30,000 restricted shares under certain corporate milestones.

On July 1, 2021, the Company engaged Peter Wanner to provide CEO duties, pursuant to the retirement of Peter Daniel Bagi.

The Company issued 100,000 shares of its unrestricted common stock at a value of \$0.40 per share initially, with further share issuance of 30,000 common shares at the beginning of each quarter of September 1 2021, December 1 2021, March 1 2022 and June 1 2022. The Company also issued a further 100,000 restricted Common Stock to Peter Wanner in recognition of work already performed for the Company.

10) Issuer Certification

Chief Executive Officer and Principal Financial Officer:

I, Peter Wanner, certify that:

1. I have reviewed this Disclosure Statement for Allstar Health Brands, Inc. (ALST);
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Aug 6, 2026

/s/ Peter Wanner